Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

High-Intensity Statin Therapy After Stroke

Stroke; ePub 2017 Sep 15; Kim, et al

High-intensity statin therapy with good adherence was significantly associated with a lower risk of adverse events after acute ischemic stroke, a recent study found. The retrospective cohort included 8,001 patients admitted with acute ischemic stroke between 2002 and 2012. Statin adherence and intensity were determined for a period of 1 year after the index stroke. The primary outcome was a composite of recurrent stroke, myocardial infarction, and all-cause mortality. Researchers found:

  • 2,284 patients developed a primary outcome during the mean follow-up period of 4.69±2.72 years.
  • Compared with patients with no statin, adjusted hazard ratios were 0.74 for good adherence, 0.93 for intermediate adherence, and 1.07 for poor adherence to statin.
  • Among the 1,712 patients with good adherence, risk of adverse events was lower in patients with high-intensity statin (aHR, 0.48), compared with those with low-intensity statin.

Citation:

Kim J, Lee HS, Nam CM, Heo JH. Effects of statin intensity and adherence on the long-term prognosis after acute ischemic stroke. [Published online ahead of print September 15, 2017]. Stroke. doi:10.1161/STROKEAHA.117.018140.

This Week's Must Reads

LDL-C Lowering with Evolocumab in Patients with PAD, Circulation; ePub 2017 Nov 13; Bonaca, et al

Does Evolocumab Lower Lipoprotein Particles?, Am J Cardiol; ePub 2017 Nov 8; Toth, et al

PCSK9 Inhibition & Neurocognitive Impairment, Circulation; ePub 2017 Nov 16; Mefford, et al

Eligibility for PCSK9 Inhibitors After ACS, J Am Heart Assoc; ePub 2017 Nov 9; Gencer, et al

CV Risk & Statins After MI in Young Adults, J Am Coll Cardiol; ePub 2017 Nov 14; Singh, et al

Must Reads in Hypercholesterolemia

LDL-C Lowering with Evolocumab in Patients with PAD, Circulation; ePub 2017 Nov 13; Bonaca, et al

Does Evolocumab Lower Lipoprotein Particles?, Am J Cardiol; ePub 2017 Nov 8; Toth, et al

PCSK9 Inhibition & Neurocognitive Impairment, Circulation; ePub 2017 Nov 16; Mefford, et al

Eligibility for PCSK9 Inhibitors After ACS, J Am Heart Assoc; ePub 2017 Nov 9; Gencer, et al

CV Risk & Statins After MI in Young Adults, J Am Coll Cardiol; ePub 2017 Nov 14; Singh, et al